The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

ResMed actually specializes in ventilators, for example against sleep apnoea. Now comes the first end customer product for ...

Well, ResMed's solution, which is at the moment the gold ... Genio is, therefore, the advanced alternative to CPAP, a kind of stepping stone, it is also more comfortable to wear.

The $120 ResMed Kontor strap has soft straps around ... It can snugly sit on my head like… well, a CPAP strap. It's also weirdly heavy with the weights on. But it makes longer sessions feel ...

Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug ... while shares of rival ResMed Inc (NYSE:RMD), which creates continuous positive airway pressure (CPAP) devices for ...

The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.